FTC Intensifies Scrutiny on Pharmaceutical Patents to Bolster Generic Drug Market
The Federal Trade Commission (FTC) has intensified its focus on pharmaceutical manufacturers’ activities regarding the listing of patents in the Orange Book. This added scrutiny aims to curb improper or inaccurate patent listings that hinder market competition and delay the entry of generic drugs. Colin Kass and David Munkittrick at Proskauer delve into the implications…